All Data
A partner for the pharma and biotech industries to improve patient outcomes & quality of life
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Tryp Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
AMRI will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: US Army
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2021
Details:
PPD will work with U.S. Army Medical Materiel Development Activity’s Warfighter Brain Health Project Management Office to test the efficacy and safety of at least two pharmacotherapeutic drugs for the treatment of PTSD in U.S. military active duty personnel and veterans.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: MYND Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2021
Details:
The collaboration aims to develop novel therapies utilizing psilocybin and other related compounds to treat Major Depressive Disorder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Mydecine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 28, 2021
Details:
The research, led by Principal Investigator Dr. Jaylyn Waddell, Assistant Professor of Neuroscience, will be testing a novel hypothesis on the mechanism of psilocybin action in a lab setting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity Corp.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2021
Details:
The Company plans to use the net proceeds of the Offering to invest in additional clinical trials, for expansion of its intellectual property portfolio, continued development of its drug pipeline, expanded R&D partnerships and initiatives and for general capital purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: LY-293,558
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 17, 2020
Details:
The grant supports development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel has demonstrated positive results in a variety of preclinical models of seizure disorder in clinical studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Sansero Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 03, 2020
Details:
Sansero Life Sciences is developing psilocybin-based pharmaceutical products to treat mental health conditions, and Rise Wellness has deep clinical and scientific expertise with psilocybin, including doing important work in both Canada and Jamaica.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane
Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cytisinicline Analogs
Therapeutic Area:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
